Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFRY ALAN JACQMEIN

Allopathic & Osteopathic Physicians Family Medicine

NPI
1588624761
CMS profile
117341
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$193.80

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $193.80 2

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme LLC $126.08 1
AstraZeneca Pharmaceuticals LP $67.72 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFRY ALAN JACQMEIN

NPI 1588624761 · CMS profile ID 117341

Allopathic & Osteopathic Physicians / Family Medicine

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFRY ALAN JACQMEIN, NPI 1588624761, CMS profile ID 117341, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1588624761?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $193.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $126.0811/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141579567 CMS
AstraZeneca Pharmaceuticals LP $67.7205/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105715512 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2024 $193.80 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,267,086.60 104
PY2024 Recipient $1,250.00 1
PY2024 Principal investigator $2,152,633.93 77
PY2023 Recipient $1,250.00 1
PY2023 Principal investigator $2,337,900.80 1,040
PY2022 Principal investigator $878,603.36 715
PY2021 Principal investigator $421,556.50 35
PY2020 Principal investigator $639,049.71 93
PY2019 Principal investigator $963,118.36 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,041 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229957
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229973
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229987
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230001
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230015
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230029
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230043
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230057
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230073
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230089
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230105
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230119
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230133
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230147
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230161
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230175
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230189
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230205
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230219
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230235
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230249
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230263
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230277
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230291
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230305
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230318
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230329
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230341
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230355
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230369
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230383
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230397
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230411
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230425
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230437
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230449
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230461
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230471
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230485
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230502
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230515
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230529
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230545
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230559
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230573
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230589
Principal investigator 1 ModernaTX, Inc. $1,605.98 12/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230603
Principal investigator 1 ModernaTX, Inc. $95,771.56 12/20/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041231409
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226029
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226043
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226057
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226071
Principal investigator 1 ModernaTX, Inc. $1,589.95 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226099
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226127
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226155
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226169
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226197
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226213
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041226229
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226257
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226271
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226287
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226301
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226315
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041226661
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226691
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226701
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226713
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226723
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226743
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226753
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226763
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226773
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226817
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226829
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226839
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226849
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226859
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226871
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226881
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041226891
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226921
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226931
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226941
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226951
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226963
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226973
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226983
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226993
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227004
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227015
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227025
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227035
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227045
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227055
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041227063
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041227073
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227097
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227107
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227117
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227129
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227139
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227149
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227159
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227169
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227179
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227189
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227199
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227213
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227235
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227247
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227257
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227267
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227275
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227287
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227297
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227319
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227329
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227337
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227349
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227361
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227375
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227389
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227403
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227417
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227433
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227449
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041227465
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227479
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227493
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227507
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227521
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227539
Principal investigator 1 ModernaTX, Inc. $1,589.95 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227553
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227593
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227607
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227621
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227635
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227649
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227663
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227675
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227691
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227703
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041227717
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041227731
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227759
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227773
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227787
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227801
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227815
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227830
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041227847
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227861
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227877
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227893
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227907
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227923
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227937
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227965
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227979
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041227993
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228007
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228021
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228039
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041228057
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228103
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228115
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228129
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228143
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228161
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228179
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041228195
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041228209
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041228223
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228239
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228251
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228265
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041228279
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228307
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228321
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228335
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228347
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228363
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228381
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228394
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228409
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228425
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041228439
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228483
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228497
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228511
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228525
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228539
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228553
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228567
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228583
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228599
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228609
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041228623
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228653
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228667
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228681
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228695
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228709
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228725
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228737
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228751
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228765
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228779
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041228793
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228811
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228823
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228837
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228851
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228879
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228895
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228907
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228923
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228937
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228951
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041228965
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041228993
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229007
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229021
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229035
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229047
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229061
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229075
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229087
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041229103
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041229115
Principal investigator 1 ModernaTX, Inc. $674.33 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041229129
Principal investigator 1 ModernaTX, Inc. $2,713.77 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229163
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229177
Principal investigator 1 ModernaTX, Inc. $2,182.38 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041229191
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229205
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229219
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229233
Principal investigator 1 ModernaTX, Inc. $1,687.26 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229247
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041229261
Principal investigator 1 ModernaTX, Inc. $1,589.95 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041230617
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/14/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041230633
Principal investigator 1 ModernaTX, Inc. $250.00 12/14/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060581
Principal investigator 1 ModernaTX, Inc. $65,438.79 12/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041231423
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226015
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226113
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226141
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226243
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226329
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226341
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226355
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226369
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226383
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226397
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226413
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226427
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226443
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226455
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226467
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226478
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226493
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226507
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226521
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226535
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226553
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226565
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226579
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226589
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226599
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226609
Principal investigator 1 ModernaTX, Inc. $1,807.87 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226619
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226629
Principal investigator 1 ModernaTX, Inc. $2,551.21 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226639
Principal investigator 1 ModernaTX, Inc. $3,661.62 12/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226651
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225341
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225355
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225369
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225383
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225397
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225413
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225429
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225443
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225459
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225473
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225503
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225519
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225547
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225561
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225575
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225589
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225603
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225617
Principal investigator 1 ModernaTX, Inc. $1,589.95 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041225631
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225647
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225661
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225679
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225693
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225707
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225737
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225751
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225765
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225779
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225793
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225809
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225821
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225837
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225853
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225866
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225883
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225897
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225911
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225925
Principal investigator 1 ModernaTX, Inc. $674.33 11/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225939
Principal investigator 1 ModernaTX, Inc. $67.00 11/16/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041215153
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $4,334.10 11/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy No dispute reported 06/30/2026 1006166051
Principal investigator 1 ModernaTX, Inc. $9,799.38 11/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225953
Principal investigator 1 ModernaTX, Inc. $2,999.95 11/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225969
Principal investigator 1 ModernaTX, Inc. $931.50 11/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225985
Principal investigator 1 ModernaTX, Inc. $171.12 11/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041226001
Principal investigator 1 ModernaTX, Inc. $67.00 10/31/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041215137
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223797
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223811
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223853
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223881
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223895
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223911
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223923
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223941
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223999
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224013
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224101
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224141
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224159
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224173
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224187
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224201
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224273
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224287
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224329
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224373
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224389
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224417
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224507
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224521
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225255
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225269
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225281
Principal investigator 1 ModernaTX, Inc. $1,002.37 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225297
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225311
Principal investigator 1 ModernaTX, Inc. $674.33 10/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041225329
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224755
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224771
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224785
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224799
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224813
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224827
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224841
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224855
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224871
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224889
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224903
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224917
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224929
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224943
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224959
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224977
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041224991
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225007
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225021
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225035
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225049
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225063
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225077
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225091
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225105
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225119
Principal investigator 1 ModernaTX, Inc. $1,605.98 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225139
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225153
Principal investigator 1 ModernaTX, Inc. $3,661.62 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225167
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225181
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225211
Principal investigator 1 ModernaTX, Inc. $1,807.87 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225225
Principal investigator 1 ModernaTX, Inc. $2,713.77 10/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225239
Principal investigator 1 ModernaTX, Inc. $1,589.95 10/26/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224073
Principal investigator 1 ModernaTX, Inc. $1,589.95 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041223825
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041223867
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041223955
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041223969
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041223983
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224029
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224043
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224057
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224127
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224213
Principal investigator 1 ModernaTX, Inc. $1,589.95 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224231
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224245
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224301
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224315
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224342
Principal investigator 1 ModernaTX, Inc. $1,589.95 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224431
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224443
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224479
Principal investigator 1 ModernaTX, Inc. $1,589.95 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224535
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224551
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224565
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224591
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224619
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224635
Principal investigator 1 ModernaTX, Inc. $2,036.58 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041224699
Principal investigator 1 Novavax Inc $3,162.91 10/05/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blinded, Phase 3 Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults No dispute reported 06/30/2026 1055261005
Principal investigator 1 ModernaTX, Inc. $750.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223051
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223065
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223079
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223093
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223107
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223135
Principal investigator 1 ModernaTX, Inc. $1,002.37 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223155
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223169
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223183
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223197
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223211
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223227
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223241
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223263
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223277
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223293
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223307
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223323
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223331
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223401
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223413
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223431
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223461
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223475
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223503
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223533
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223547
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223561
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223617
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223649
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223661
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223677
Principal investigator 1 ModernaTX, Inc. $674.33 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223691
Principal investigator 1 ModernaTX, Inc. $750.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223707
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223723
Principal investigator 1 ModernaTX, Inc. $250.00 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223737
Principal investigator 1 ModernaTX, Inc. $236.25 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224669
Principal investigator 1 ModernaTX, Inc. $3,213.67 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041224713
Principal investigator 1 ModernaTX, Inc. $4,500.05 10/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041225195
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222439
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222497
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222551
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222565
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222581
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222595
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222609
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222623
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222637
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222651
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222665
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222697
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222713
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222729
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222743
Principal investigator 1 ModernaTX, Inc. $1,002.37 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222757
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222771
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222787
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222801
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222831
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222893
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222907
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222921
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222977
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041222993
Principal investigator 1 ModernaTX, Inc. $674.33 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041223009
Principal investigator 1 ModernaTX, Inc. $10,000.00 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041223751
Principal investigator 1 ModernaTX, Inc. $1,250.00 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041223765
Principal investigator 1 ModernaTX, Inc. $2,390.00 09/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 1/2, randomized, observer-blind, placebo-controlled, dose-rangingstudy to evaluate the safety and immunogenicity of heptavalent mRNA-1975 (SR1-7) and monovalent mRNA-1982 (SR1) in parallel againstLyme disease in healthy participants 18 through 70 years of age No dispute reported 06/30/2026 1041223783
Principal investigator 1 ModernaTX, Inc. $375.00 09/11/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060471
Principal investigator 1 ModernaTX, Inc. $1,589.95 09/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222411
Principal investigator 1 ModernaTX, Inc. $2,036.58 09/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222481
Principal investigator 1 ModernaTX, Inc. $2,036.58 09/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222535
Principal investigator 1 ModernaTX, Inc. $2,036.58 09/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222865
Principal investigator 1 ModernaTX, Inc. $1,589.95 09/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222963
Principal investigator 1 Janssen Pharmaceuticals, Inc $27,070.00 09/06/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093405
Principal investigator 1 Novavax Inc $8,243.00 09/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258867
Principal investigator 1 Janssen Pharmaceuticals, Inc $356.00 09/01/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093403
Principal investigator 1 Novavax Inc $4,794.00 09/01/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264745
Principal investigator 1 Novavax Inc $40,264.00 08/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260833
Principal investigator 1 Janssen Pharmaceuticals, Inc $14,415.00 08/02/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093407
Principal investigator 1 Novavax Inc $120.00 07/26/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263741
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,984.00 07/21/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093401
Principal investigator 1 Novavax Inc $240.00 07/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261811
Principal investigator 1 Novavax Inc $840.00 07/11/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261809
Principal investigator 1 Novavax Inc $1,916.00 07/04/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263739
Principal investigator 1 Novavax Inc $1,399.00 06/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263737
Principal investigator 1 Janssen Pharmaceuticals, Inc $170.00 06/21/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093399
Principal investigator 1 Novavax Inc $4,954.00 06/20/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055261807
Principal investigator 1 Novavax Inc $5,471.00 06/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258865
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218911
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218925
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218939
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218955
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218971
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218985
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041218999
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219013
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219027
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219041
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219057
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219073
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219087
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219101
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219115
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219129
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219145
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219157
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219171
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219187
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219199
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219213
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219227
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219243
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219259
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219275
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219289
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219303
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219317
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219331
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219346
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219363
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219375
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219389
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219403
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219493
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219515
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219529
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219543
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219557
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219573
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219587
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219601
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219615
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219629
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219643
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219657
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219673
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219687
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219701
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219715
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219731
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219747
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219761
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219777
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219793
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219805
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219821
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219835
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219849
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219863
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219877
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219891
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219907
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219921
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219935
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219949
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219963
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219977
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219991
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220005
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220019
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220031
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220047
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220061
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220075
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220089
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220103
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220119
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220133
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220147
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220161
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220175
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220190
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220205
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220219
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220231
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220245
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220257
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220275
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220291
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220305
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220319
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220333
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220349
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220367
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220379
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220393
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220407
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220423
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220439
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220453
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220467
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220481
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220497
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220511
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220525
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220541
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220553
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220567
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220585
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220601
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220615
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220631
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220645
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220659
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220673
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220687
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220701
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220717
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220731
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220745
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220759
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220773
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220785
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220799
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220813
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220828
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220845
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220859
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220867
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220877
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220891
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220907
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220919
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220933
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220951
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220965
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220979
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041220993
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221007
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221021
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221035
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221049
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221065
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221081
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221095
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221109
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221125
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221139
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221153
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221167
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221181
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221197
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221209
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221219
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221231
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221241
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221251
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221265
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221275
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221285
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221295
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221305
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221315
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221327
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221341
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221355
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221371
Principal investigator 1 ModernaTX, Inc. $4,271.34 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221385
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221401
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221417
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221431
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221446
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221461
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221477
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221491
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221507
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221523
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221539
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221553
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221565
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221583
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221595
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221610
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221625
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221639
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221653
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221665
Principal investigator 1 ModernaTX, Inc. $1,848.26 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221683
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221699
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221713
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221727
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221741
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221755
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221769
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221785
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221799
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221813
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221831
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221845
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221858
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221871
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221885
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221899
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221915
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221928
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221943
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221959
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221973
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041221987
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222001
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222015
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222031
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222045
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222060
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222075
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222091
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222107
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222121
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222135
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222151
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222165
Principal investigator 1 ModernaTX, Inc. $2,833.62 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222181
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222195
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222209
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222221
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222237
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222253
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222269
Principal investigator 1 ModernaTX, Inc. $630.59 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222283
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222297
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222311
Principal investigator 1 ModernaTX, Inc. $2,711.88 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222325
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222339
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222355
Principal investigator 1 ModernaTX, Inc. $721.71 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222369
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222383
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041222397
Principal investigator 1 Novavax Inc $3,919.00 06/08/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262837
Principal investigator 1 ModernaTX, Inc. $500.00 06/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219421
Principal investigator 1 ModernaTX, Inc. $1,000.00 06/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219434
Principal investigator 1 ModernaTX, Inc. $2,500.00 06/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219447
Principal investigator 1 ModernaTX, Inc. $1,250.00 06/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219465
Principal investigator 1 ModernaTX, Inc. $10,000.00 06/07/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041219479
Principal investigator 1 Novavax Inc $2,040.00 05/30/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265785
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,100.00 05/24/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093397
Principal investigator 1 Novavax Inc $5,157.00 05/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265787
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218319
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218333
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218347
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218361
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218375
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218391
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218421
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218435
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218449
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218467
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218483
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218539
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218553
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218569
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218611
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218627
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218641
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218655
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218669
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218685
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218727
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218742
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218755
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218769
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218783
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218797
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218811
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218827
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218841
Principal investigator 1 ModernaTX, Inc. $674.33 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218883
Principal investigator 1 ModernaTX, Inc. $1,002.37 05/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218897
Principal investigator 1 Novavax Inc $3,919.00 05/16/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259833
Principal investigator 1 Novavax Inc $5,959.00 05/09/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264743
Principal investigator 1 Novavax Inc $228.00 05/09/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055265789
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060189
Principal investigator 1 ModernaTX, Inc. $6,995.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060409
Principal investigator 1 Novavax Inc $1,680.00 05/03/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263735
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217525
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217539
Principal investigator 1 ModernaTX, Inc. $60.76 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217569
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217611
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217627
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217643
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217659
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217671
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217687
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217701
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217715
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217729
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217743
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217757
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217771
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217785
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217799
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217815
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217829
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217845
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217861
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217875
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217901
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217916
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217931
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217945
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217959
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217987
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218005
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218019
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218033
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218047
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218061
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218075
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218089
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218104
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218119
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218135
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218148
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218177
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218191
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218205
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218219
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218231
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218245
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218261
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218275
Principal investigator 1 ModernaTX, Inc. $674.33 04/27/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041218289
Principal investigator 1 Novavax Inc $4,531.00 04/26/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265781
Principal investigator 1 Novavax Inc $4,113.00 04/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258863
Principal investigator 1 Novavax Inc $7,892.00 04/18/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265791
Principal investigator 1 Novavax Inc $1,424.00 04/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263733
Principal investigator 1 Novavax Inc $20,498.00 04/04/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265783
Principal investigator 1 ModernaTX, Inc. $166.50 03/29/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041560747
Principal investigator 1 Novavax Inc $6,991.00 03/29/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258861
Principal investigator 1 Novavax Inc $1,080.00 03/29/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055264741
Principal investigator 1 Novavax Inc $3,568.00 03/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055258859
Principal investigator 1 Novavax Inc $4,320.00 03/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262833
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,132.00 03/22/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093383
Principal investigator 1 Novavax Inc $2,520.00 03/21/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262831
Principal investigator 1 Novavax Inc $8,781.00 03/15/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260829
Principal investigator 1 Novavax Inc $5,932.00 03/15/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260831
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216601
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216659
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216675
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216691
Principal investigator 1 ModernaTX, Inc. $1,002.37 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216751
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216807
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216823
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216851
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216935
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216950
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216969
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216983
Principal investigator 1 ModernaTX, Inc. $1,002.37 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217033
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217089
Principal investigator 1 ModernaTX, Inc. $14.58 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217105
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217149
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217209
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217225
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217295
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217365
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217427
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217483
Principal investigator 1 ModernaTX, Inc. $674.33 03/13/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041217511
Principal investigator 1 Novavax Inc $4,660.00 03/08/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259831
Principal investigator 1 Novavax Inc $62,864.00 03/08/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262835
Principal investigator 1 Novavax Inc $4,320.00 02/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055259829
Principal investigator 1 Novavax Inc $28,904.00 02/28/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055262827
Principal investigator 1 ModernaTX, Inc. $765.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215439
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215455
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215469
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215483
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215513
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215527
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215541
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215555
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215569
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215585
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215603
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215615
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215630
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215643
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215661
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215675
Principal investigator 1 ModernaTX, Inc. $765.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215689
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215701
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215715
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215729
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215745
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215759
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215773
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215787
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215801
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215813
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215827
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215836
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215849
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215861
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215877
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215891
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215904
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215917
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215927
Principal investigator 1 ModernaTX, Inc. $1,002.37 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215937
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215948
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215963
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215977
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216005
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216019
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216031
Principal investigator 1 ModernaTX, Inc. $765.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216045
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216059
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216073
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216107
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216121
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216133
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216179
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216197
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216211
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216225
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216239
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216253
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216267
Principal investigator 1 ModernaTX, Inc. $1,002.37 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216283
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216297
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216311
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216325
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216337
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216353
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216369
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216383
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216395
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216409
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216425
Principal investigator 1 ModernaTX, Inc. $522.45 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216439
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216457
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216471
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216485
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216499
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216513
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216527
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216555
Principal investigator 1 ModernaTX, Inc. $14.58 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216569
Principal investigator 1 ModernaTX, Inc. $674.33 02/24/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041216585
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,211.00 02/23/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093385
Principal investigator 1 Novavax Inc $16,720.00 02/22/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263731
Principal investigator 1 Novavax Inc $42,468.00 02/22/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055264739
Principal investigator 1 Novavax Inc $51,884.00 02/16/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055262829
Principal investigator 1 Novavax Inc $4,652.00 02/16/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263729
Principal investigator 1 SANOFI PASTEUR INC. $3,150.00 02/10/2023 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune Vaccine or MenACYW Conjugate Vaccine in Older Adults No dispute reported 06/30/2026 1035886183
Principal investigator 1 ABBVIE INC. $1,110.60 02/09/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RE
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998369505
Principal investigator 1 Novavax Inc $71,226.00 02/09/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263725
Principal investigator 1 Novavax Inc $4,172.00 02/09/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264737
Principal investigator 1 Novavax Inc $4,532.00 02/02/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055265779
Principal investigator 1 Biogen, Inc. $62,753.00 01/25/2023 Non-covered Recipient Entity
Jacksonville Center For Clinical Research
Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimers disease Who Had Previously Participated in the Aducanumab Studies221AD103, 221AD301, 221AD302 and 221AD205 No dispute reported 06/30/2026 1012172775
Principal investigator 1 Janssen Pharmaceuticals, Inc $14,216.00 01/25/2023 Non-covered Recipient Entity
Jacksonville Ctr For Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093387
Principal investigator 1 Novavax Inc $3,360.00 01/25/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055264735
Principal investigator 1 Novavax Inc $226,208.00 01/20/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055258857
Principal investigator 1 Novavax Inc $7,026.00 01/20/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055263727
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213767
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213783
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213799
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213827
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213841
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213853
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213883
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213897
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213911
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213939
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213953
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213967
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213981
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041213995
Principal investigator 1 ModernaTX, Inc. $1,002.37 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214009
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214023
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214037
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214095
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214109
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214125
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214139
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214153
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214165
Principal investigator 1 ModernaTX, Inc. $674.33 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214209
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214225
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214239
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214253
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214267
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214281
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214345
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214359
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214385
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214417
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214429
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214443
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214471
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214483
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214499
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214510
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214539
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214569
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214581
Principal investigator 1 ModernaTX, Inc. $1,002.37 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214701
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214743
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214757
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214771
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214783
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214815
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214857
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214875
Principal investigator 1 ModernaTX, Inc. $3,213.67 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214891
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214905
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214919
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214933
Principal investigator 1 ModernaTX, Inc. $765.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214945
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214961
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214975
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041214989
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215002
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215087
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215165
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215179
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215226
Principal investigator 1 ModernaTX, Inc. $674.33 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215241
Principal investigator 1 ModernaTX, Inc. $674.33 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215255
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215291
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215305
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215321
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215337
Principal investigator 1 ModernaTX, Inc. $522.45 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215353
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215395
Principal investigator 1 ModernaTX, Inc. $14.58 01/12/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041215411
Recipient SANOFI PASTEUR INC. $1,250.00 01/11/2023 Covered Recipient Physician Safety and Immunogenicity of a Single Dose of MenACYW Conjugate Vaccine at Least 3 Years Following Initial Vaccination With Either Menomune Vaccine or MenACYW Conjugate Vaccine in Older Adults No dispute reported 06/30/2026 1035885597
Principal investigator 1 Novavax Inc $3,982.00 01/10/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055259827
Principal investigator 1 Novavax Inc $19,484.00 01/10/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055260827
Principal investigator 1 Novavax Inc $30,242.00 01/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 No dispute reported 06/30/2026 1055260825
Principal investigator 1 Novavax Inc $28,167.00 01/06/2023 Non-covered Recipient Entity
JACKSONVILLE CENTER FOR CLINICAL RESEARCH
A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) No dispute reported 06/30/2026 1055263723